SCHEMBL6074566

SCHEMBL6074566

COc1ccc2c(c1)N(C)C(=O)C2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
LMNA P02545 1/20 0.53
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
KMT2A Q03164 3/20 0.48
CASP1 P29466 1/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
DRD2 P14416 3/20 0.47
DRD1 P21728 3/20 0.47
DRD5 P21918 3/20 0.47
DRD3 P35462 3/20 0.47
MEN1 O00255 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
METAP1 P53582 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853451 0.87 METAP1 (0.53) HTTLMNAALDH1A1HPGDKMT2A
SCHEMBL26768760 0.87 METAP1 (0.53) HTTLMNAALDH1A1HPGDKMT2A
SCHEMBL578369 0.86 LMNA (0.60) HTTLMNAALDH1A1HPGDKMT2A
SCHEMBL6073593 0.85 CYP11B1 (0.52) HTTLMNACYP1A2CYP3A4DRD2
SCHEMBL14521049 0.82 CDC25A (0.52) HTTLMNAALDH1A1KMT2AGAA
SCHEMBL15964822 0.82 LMNA (0.49) HTTLMNACYP1A2DRD2DRD1
SCHEMBL7684008 0.81 KYAT1 (0.58) HTTLMNAALDH1A1HPGDKMT2A
SCHEMBL8998821 0.81 GLA (0.45) HTTLMNAALDH1A1GAAKDM4E
SCHEMBL27326147 0.81 ALDH1A1 (0.53) HTTLMNAALDH1A1HPGDKMT2A
SCHEMBL9922257 0.80 METAP1 (0.55) ALDH1A1HPGDKMT2ACASP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024121259-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-06-13 WO disclosed
CN-115636778-B Synthesis method of 3-quaternary carbon substituted indoline-2-ketone compound 常州大学 2024-05-07 CN disclosed
CN-115636778-A Synthetic method of 3-quaternary carbon substituted indoline-2-ketone compound 常州大学 2023-01-24 CN disclosed
WO-2012049555-A1 SPIROCYCLIC COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS LUPIN LIMITED (IN) 2012-04-19 WO disclosed
US-7119207-B2 Benzoamide piperidine containing compounds and related compounds PFIZER INC (US) 2006-10-10 US disclosed
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds PFIZER INC. 2003-05-08 US disclosed
EP-1272484-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS Pfizer Products Inc. (US) 2003-01-08 EP disclosed
WO-2001077100-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PRODUCTS INC. (US) 2001-10-18 WO disclosed
US-5556874-A ENZYME INHIBITORS AS ANTICARCINOGENIC AGENTS WARNER LAMBERT COMPANY (US) 1996-09-17 US disclosed
US-5464861-A Anticarcinogenic agents WARNER-LAMBERT (US) 1995-11-07 US disclosed
EP-0654024-A1 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES WARNER-LAMBERT COMPANY (US) 1995-05-24 EP disclosed
WO-1994003427-A1 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES WARNER-LAMBERT COMPANY (US) 1994-02-17 WO disclosed
US-5030646-A Treatment of diseases resulting from disfunction of seretoninergic system ADIR ET COMPAGNIE (FR) 1991-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds TACR1, VIPR1, VIPR2 HTT 868/4885LMNA 3704/4885ALDH1A1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.